Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z)
March 26 (Reuters) - Intellia Therapeutics Inc NTLA.O:
INTELLIA THERAPEUTICS ANNOUNCES FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION GRANTED TO NEXIGURAN ZICLUMERAN (NEX-Z) FOR THE TREATMENT OF TRANSTHYRETIN (ATTR) AMYLOIDOSIS WITH CARDIOMYOPATHY
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Musk’s XChat Is Coming to App Store, Meta, Apple and Finance World Are Trembling

Anthropic IPO 2026: What the Claude Mythos Release Delay Means for Investors and Stock Valuation

Microsoft Launches Its Own AI Models and Ditches OpenAI Dependence - Is MSFT Stock a Buy at $370?

Anthropic Claude Mythos Preview Sparks Wall Street Panic: Bessent, Powell Summon CEOs; Cloudflare Tumbles 8%

Intel Stock's Rare Surge: What’s Driving the Rally and Is It Worth Buying in 2026?

Tradingkey







